aliquot

Mitochondrial-related

SS-31 / Elamipretide

An Aliquot catalog identity that names SS-31 with elamipretide. FDA granted accelerated approval to an elamipretide product for a specific labeled use in 2025.

Canonical ID
ss-31
Evidence type
FDA accelerated-approval record and prescribing information
Human PK
Not published

Overview

Aliquot distinguishes the specific approved product from the broader catalog identity and does not extend the label beyond what it supports.

The current FDA label is used for regulatory context. Aliquot withholds a half-life because the label does not publish one.

Human pharmacokinetic context

Not published

Aliquot has not published a route-matched human half-life statement for this entry.

Half-life is descriptive population context, not a dosing interval, a prediction of an individual's response, or a recommendation. Route-mismatched and uncited estimates are withheld.

Limitations

  • Accelerated approval is specific to the named product and labeled population; it does not validate other products or uses.
  • No elimination half-life is published from the current label.

Related calculation tools

Aliquot's browser-only tools transform values you already have. They do not select a compound, suggest an amount, provide presets, or store your entries.

View all tools Convert mg and mcg

Sources

  1. FDA grants accelerated approval to first treatment for Barth syndrome FDA approval announcement · U.S. Food and Drug Administration · accessed 2026-07-28 Accelerated approval date and narrow regulatory context.
  2. Forzinity (elamipretide) prescribing information FDA prescribing information · U.S. Food and Drug Administration · accessed 2026-07-28 Current prescribing information and PK limitation.
  3. Aliquot compound library methodology Editorial methodology · Aliquot · accessed 2026-07-28 Editorial scope and withholding rules.

Aliquot Compound Library

Before you browse

Aliquot's Compound Library is an educational reference. Here is how to read and use it.

Educational, not medical advice

The library does not diagnose, treat, prevent, recommend a compound, or replace a licensed clinician. Consult a qualified clinician for personal health decisions.

Evidence has boundaries

Summaries draw from cited public regulator records, peer-reviewed human studies, PubMed records, and trial registrations. A citation does not make a claim conclusive.

No community health profiles

Aliquot does not collect community protocols or outcomes for this library. Calculator entries remain in your browser tab and are not submitted or saved.

Content and reuse

Aliquot's original editorial text and presentation may not be copied, scraped, mirrored, or redistributed without written permission. Linked sources remain subject to their publishers' terms.

This acknowledgement is stored only in this browser. No health or calculator data is included.

Methodology Terms

Reviewed by Aliquot editorial review on 2026-07-28. Next scheduled review: 2026-10-26. Methodology and corrections.